Adela Castro/X
Nov 14, 2026, 14:24
Adela Castro: Distinguishing Antiphospholipid Antibodies From APS in Pregnancy
Adela Castro, Assistant Professor of Rheumatology at University of Tennessee Health Science Center (Memphis), shared a post on X:
“APL versus APS in Pregnancy: Same Antibody, Different Plan
- APL but no APS: no anticoagulation; low-dose aspirin (LDASA) may reduce preeclampsia risk
- Obstetric APS: LDASA plus prophylactic LMWH, continued through 6 weeks postpartum
- Thrombotic APS: LDASA plus treatment-dose LMWH; consider HCQ
About 20 percent of pregnancies still fail despite LMWH, because placental injury is also inflammatory and complement-mediated, so consider HCQ.
IMPACT study: adding certolizumab to standard APS care appeared to increase live birth rates and reduce adverse pregnancy outcomes.”
Stay updated with Hemostasis Today.
-
Nov 14, 2026, 14:20Uzima Chirwa: Rethinking Comprehensive Care for Bleeding Disorders in Africa
-
Nov 14, 2026, 14:19Samuele Ferrari: Launching a New Era in Hematopoietic Genome Editing Research
-
Nov 14, 2026, 14:17Stefan Hofer: International Training in Postpartum Hemorrhage Management
-
Nov 14, 2026, 14:14Expanding Global Access to Gene Therapy – WFH
-
Nov 14, 2026, 14:11Cedric Hermans: Advancing Haemophilia Care Through Innovation and Global Access
-
Nov 14, 2026, 14:08Bruno Pougault: Lupus Anticoagulant Testing During DOAC Therapy
-
Nov 14, 2026, 14:08Francinny Alves Kelly: AHA Scientific Sessions 2026 Features Research on CHA₂DS₂-VASc and Transhepatic AF Ablation
-
Nov 14, 2026, 14:03Newborn Vitamin K Prophylaxis and the Risk of Bleeding – JAMA
-
Nov 14, 2026, 14:03Denis Oduor: Shaping the Future of Transfusion Medicine at Terumo BCT Africa Hackathon 2026